RT Journal
A1 Kuehn BM
T1 TElaprevir warning
JF JAMA
JO JAMA
YR 2013
FD January 23
VO 309
IS 4
SP 333
OP 333
DO 10.1001/jama.2013.22
UL http://dx.doi.org/10.1001/jama.2013.22
AB 
The label for telaprevir already warns about the potential for serious skin reactions such as Stevens-Johnson syndrome and drug rash with eosinophilia and systemic symptoms (DRESS). But the FDA has now received 2 reports from Japan of toxic epidermal necrolysis in patients taking telaprevir combination therapy. One of the patients died after therapy was continued despite signs of a skin reaction. The FDA has also received a report of a woman who had developed DRESS and died after telaprevir combination treatment was continued.